Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy.
OBJECTIVE
To identify clinical characteristics associated with developing persistent gestational trophoblastic neoplasia (GTN) after partial hydatidiform molar pregnancy (PHM).


METHODS
Utilizing the Donald P. Goldstein in patients who developed persistence between 1973 and 1989.


CONCLUSIONS
Older age at diagnosis and history of prior mole were significantly more common in women who developed persistence after partial molar pregnancy in referral of patients the earlier cohort but not in idefined clinical the recent cohort. In recent years no clinical factor was at increase their risk significantly associated with rsistence. database at the New England Trophoblastic Disease Center, 284 women with partial molar pregnancy diagnosed between 1973 and 2003 were characteristics identified. Clinical charac- for pe teristics, such as gravidity, parity, age, uterine size, gestational age at diagnosis, human chorionic gonadotropin levels at presentation and time to development of persistence (GTN) were analyzed. Data were also divided into 2 cohorts, an earlier one (1973-1989) and a later one (1990-2003), in order to look at potential changes over time.


RESULTS
GTN developed in 5.6% of partial molar pregnancies. Older maternal age was significantly associated with development of persistent GTN in the earlier cohort but not in the recent cohort. Previous molar pregnancy was also statistically significantly more common the development of +/-after PHM.
Feltmate
Colleen M
CM
Donald P. Goldstein, M.D., Trophoblastic Tumor Registry, New England Trophoblastic Disease Center, USA. cfeltmate@partners.org
Growdon
Whitfield B
WB
Wolfberg
Adam J
AJ
Goldstein
Donald P
DP
Genest
David R
DR
Chinchilla
Manuel E
ME
Lieberman
Ellice S
ES
Berkowitz
Ross S
RS
D000328:Adult; D006063:Chorionic Gonadotropin / Q000097:blood*; D015331:Cohort Studies; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000097:blood* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D020073:Gravidity; D006801:Humans; D006828:Hydatidiform Mole / Q000097:blood* / Q000453:epidemiology / Q000628:therapy; D008423:Maternal Age; D009511:New England; D011247:Pregnancy; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors
D006063:Chorionic Gonadotropin